These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23496322)

  • 1. Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factor.
    Schwöppe C; Zerbst C; Fröhlich M; Schliemann C; Kessler T; Liersch R; Overkamp L; Holtmeier R; Stypmann J; Dreiling A; König S; Höltke C; Lücke M; Müller-Tidow C; Mesters RM; Berdel WE
    J Med Chem; 2013 Mar; 56(6):2337-47. PubMed ID: 23496322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR.
    Brand C; Fröhlich M; Ring J; Schliemann C; Kessler T; Mantke V; König S; Lücke M; Mesters RM; Berdel WE; Schwöppe C
    Mol Pharm; 2015 Oct; 12(10):3749-58. PubMed ID: 26310827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
    Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
    Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
    Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
    Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor.
    Brand C; Schliemann C; Ring J; Kessler T; Bäumer S; Angenendt L; Mantke V; Ross R; Hintelmann H; Spieker T; Wardelmann E; Mesters RM; Berdel WE; Schwöppe C
    Oncotarget; 2016 Feb; 7(6):6774-89. PubMed ID: 26735180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor.
    Brand C; Dencks S; Schmitz G; Mühlmeister M; Stypmann J; Ross R; Hintelmann H; Schliemann C; Müller-Tidow C; Mesters RM; Berdel WE; Schwöppe C
    J Ultrasound Med; 2015 Jul; 34(7):1227-36. PubMed ID: 26112625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.
    Persigehl T; Ring J; Bremer C; Heindel W; Holtmeier R; Stypmann J; Claesener M; Hermann S; Schäfers M; Zerbst C; Schliemann C; Mesters RM; Berdel WE; Schwöppe C
    Angiogenesis; 2014 Jan; 17(1):235-46. PubMed ID: 24136410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.
    Bieker R; Kessler T; Schwöppe C; Padró T; Persigehl T; Bremer C; Dreischalück J; Kolkmeyer A; Heindel W; Mesters RM; Berdel WE
    Blood; 2009 May; 113(20):5019-27. PubMed ID: 19179306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma.
    Brand C; Greve B; Bölling T; Eich HT; Willich N; Harrach S; Hintelmann H; Lenz G; Mesters RM; Kessler T; Schliemann C; Berdel WE; Schwöppe C
    PLoS One; 2020; 15(2):e0229271. PubMed ID: 32084238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-factor fusion proteins induce occlusion of tumor vessels.
    Schwöppe C; Kessler T; Persigehl T; Liersch R; Hintelmann H; Dreischalück J; Ring J; Bremer C; Heindel W; Mesters RM; Berdel WE
    Thromb Res; 2010 Apr; 125 Suppl 2():S143-50. PubMed ID: 20433995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.
    Schmidt LH; Stucke-Ring J; Brand C; Schliemann C; Harrach S; Muley T; Herpel E; Kessler T; Mohr M; Görlich D; Kreuter M; Lenz G; Wardelmann E; Thomas M; Berdel WE; Schwöppe C; Hartmann W
    Lung Cancer; 2017 Nov; 113():121-127. PubMed ID: 29110838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells.
    Wang X; Wang Y; Chen X; Wang J; Zhang X; Zhang Q
    J Control Release; 2009 Oct; 139(1):56-62. PubMed ID: 19470394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats.
    Zhao BJ; Ke XY; Huang Y; Chen XM; Zhao X; Zhao BX; Lu WL; Lou JN; Zhang X; Zhang Q
    J Drug Target; 2011 Jun; 19(5):382-90. PubMed ID: 20677914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
    Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature.
    Kessler T; Bieker R; Padró T; Schwöppe C; Persigehl T; Bremer C; Kreuter M; Berdel WE; Mesters RM
    Clin Cancer Res; 2005 Sep; 11(17):6317-24. PubMed ID: 16144936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
    Zheng YB; Shang BY; Li Y; Zhen YS
    Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylation improves the pharmacokinetics and bioavailability of small-molecule drugs hydrolyzable by esterases: a study of phospho-Ibuprofen.
    Mattheolabakis G; Wong CC; Sun Y; Amella CA; Richards R; Constantinides PP; Rigas B
    J Pharmacol Exp Ther; 2014 Oct; 351(1):61-6. PubMed ID: 25047517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.
    Yoshioka Y; Tsutsumi Y; Ikemizu S; Yamamoto Y; Shibata H; Nishibata T; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Nagata S; Yamagata Y; Mayumi T
    Biochem Biophys Res Commun; 2004 Mar; 315(4):808-14. PubMed ID: 14985084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
    Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
    Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.
    Däpp S; García Garayoa E; Maes V; Brans L; Tourwé DA; Müller C; Schibli R
    Nucl Med Biol; 2011 Oct; 38(7):997-1009. PubMed ID: 21982571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.